Myriad Genetics, Inc. $MYGN Shares Acquired by Aberdeen Group plc

Aberdeen Group plc grew its position in Myriad Genetics, Inc. (NASDAQ:MYGN) by 178.3% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 639,053 shares of the company’s stock after buying an additional 409,460 shares during the quarter. Aberdeen Group plc’s holdings in Myriad Genetics were worth $4,620,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Abich Financial Wealth Management LLC acquired a new position in Myriad Genetics in the 3rd quarter valued at $61,000. Public Sector Pension Investment Board grew its holdings in shares of Myriad Genetics by 15.5% during the third quarter. Public Sector Pension Investment Board now owns 362,917 shares of the company’s stock worth $2,624,000 after buying an additional 48,691 shares in the last quarter. Cornerstone Investment Partners LLC acquired a new stake in shares of Myriad Genetics in the third quarter valued at about $207,000. Plan A Wealth LLC acquired a new stake in shares of Myriad Genetics in the third quarter valued at about $77,000. Finally, Hantz Financial Services Inc. lifted its stake in shares of Myriad Genetics by 1,088.7% in the third quarter. Hantz Financial Services Inc. now owns 4,089 shares of the company’s stock worth $30,000 after buying an additional 3,745 shares in the last quarter. 99.02% of the stock is owned by institutional investors and hedge funds.

Myriad Genetics Price Performance

MYGN stock opened at $4.29 on Friday. Myriad Genetics, Inc. has a 52-week low of $3.76 and a 52-week high of $15.18. The company has a quick ratio of 2.12, a current ratio of 2.33 and a debt-to-equity ratio of 0.32. The stock has a market cap of $399.87 million, a price-to-earnings ratio of -0.99 and a beta of 1.90. The business has a fifty day moving average of $5.83 and a two-hundred day moving average of $6.63.

Analysts Set New Price Targets

Several analysts recently issued reports on the stock. Zacks Research cut shares of Myriad Genetics from a “hold” rating to a “strong sell” rating in a research note on Monday, January 19th. TD Cowen restated a “hold” rating on shares of Myriad Genetics in a report on Tuesday, November 4th. Wells Fargo & Company upped their price target on Myriad Genetics from $6.00 to $6.50 and gave the company an “equal weight” rating in a research report on Wednesday, November 5th. UBS Group lifted their price objective on Myriad Genetics from $6.00 to $8.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 4th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Myriad Genetics in a research note on Monday, December 29th. Four investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Myriad Genetics currently has an average rating of “Hold” and an average price target of $9.44.

About Myriad Genetics

Myriad Genetics (NASDAQ: MYGN) is a molecular diagnostics company that develops and commercializes genetic tests designed to assess an individual’s risk for various hereditary conditions and to guide personalized treatment decisions. The company’s core business centers on predictive medicine, with a focus on hereditary cancer risk assessment through its flagship BRACAnalysis® test for BRCA1 and BRCA2 gene mutations. In addition to oncology, Myriad offers tests in women’s health, neurology and pharmacogenomics to support more informed clinical decision-making.

Among its product offerings are the myRisk® Hereditary Cancer test, which screens for mutations across multiple cancer-related genes, and Prequel®, a non-invasive prenatal test for assessing fetal chromosomal abnormalities.